Aurora, Colorado
Cancer clinical trials in Aurora, CO
167 cancer studies are recruiting participants at sites in Aurora as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Aurora at a glance
- 167 studies are recruiting at a site in Aurora.
- By phase: Phase 1 (24), Phase 1/2 (32), Phase 2 (26), Phase 2/3 (4), Phase 3 (51), Phase 4 (1), No phase (6), Observational (23). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (93), university, hospital or other (61), government (13).
- By research area: Breast Cancer (45), Lung Cancer (42), Lymphoma (36), Prostate Cancer (18), Melanoma (17), Pancreatic Cancer (9).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in Aurora
Basic details from each study's public record (the 30 most recently updated of 167). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Colorado Anschutz Medical Campus ( Site 0057)
- Registry record
- NCT06686394 · updated
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UCHealth University of Colorado Hospital
- Registry record
- NCT03606967 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UCHealth University of Colorado Hospital
- Registry record
- NCT05564377 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UCHealth University of Colorado Hospital
- Registry record
- NCT06058377 · updated
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Rocky Mountain Cancer Centers-Aurora
- Registry record
- NCT03723928 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Aurora, CO on ClinicalTrials.gov.
Lung cancer studies recruiting in Aurora
Targeted Telerehabilitation Following Curative Intent Therapy of Lung Cancer
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- VA Office of Research and Development
- Study site
- Rocky Mountain Regional VA Medical Center, Aurora, CO
- Registry record
- NCT05179408 · updated
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 to 99
- All sexes
- Sponsor
- Erasca, Inc.
- Study site
- University of Colorado
- Registry record
- NCT06983743 · updated
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Colorado Cancer Center ( Site 3268)
- Registry record
- NCT07513376 · updated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- University of Colorado Cancer Center
- Registry record
- NCT07659782 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Rocky Mountain Cancer Centers-Aurora · UCHealth University of Colorado Hospital
- Registry record
- NCT04267848 · updated
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- SystImmune Inc.
- Study site
- University of Colorado - Anschutz Cancer Pavilion
- Registry record
- NCT07080242 · updated
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Phase 2
- Ages 18 to 80
- All sexes
- Sponsor
- Reunion Neuroscience Inc
- Study site
- University of Colorado
- Registry record
- NCT07002034 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Colorado Anschutz Medical Campus ( Site 0151)
- Registry record
- NCT06623422 · updated
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Colorado, Anschutz Cancer Pavilion ( Site 0125)
- Registry record
- NCT07227597 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Aurora, CO on ClinicalTrials.gov.
Prostate cancer studies recruiting in Aurora
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- VA Office of Research and Development
- Study site
- Rocky Mountain Regional VA Medical Center, Aurora, CO
- Registry record
- NCT04038502 · updated
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- VA Office of Research and Development
- Study site
- Rocky Mountain Regional VA Medical Center, Aurora, CO
- Registry record
- NCT05011383 · updated
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Anschutz Cancer Pavilion ( Site 0046)
- Registry record
- NCT06136624 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Aurora, CO on ClinicalTrials.gov.
Melanoma studies recruiting in Aurora
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- UCHealth University of Colorado Hospital
- Registry record
- NCT07068074 · updated
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Phase 1/2
- From 6 months, up to 17 years
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Call for Information (Investigational Site 0019)
- Registry record
- NCT02332668 · updated
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study sites
- Rocky Mountain Regional VA Medical Center · University of Colorado Cancer Center
- Registry record
- NCT06246916 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Aurora, CO on ClinicalTrials.gov.
Lymphoma studies recruiting in Aurora
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Rocky Mountain Cancer Centers, LLP
- Registry record
- NCT06806033 · updated
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Nurix Therapeutics, Inc.
- Study site
- Rocky Mountain Cancer Centers
- Registry record
- NCT07520006 · updated
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Phase 1
- Ages 0 to 18
- All sexes
- Sponsor
- Autolus Limited
- Study site
- Children's Hospital Colorado
- Registry record
- NCT06173518 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Rocky Mountain Cancer Centers (RMCC) ( Site 8001)
- Registry record
- NCT06890884 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Children's Hospital Colorado
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's Hospital Colorado · UCHealth University of Colorado Hospital
- Registry record
- NCT05675410 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UCHealth University of Colorado Hospital
- Registry record
- NCT06337318 · updated
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- Rocky Mountain Cancer Centers (Williams) Usor
- Registry record
- NCT06846671 · updated
Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
- Observational
- Ages 8 and older
- All sexes
- Sponsor
- St. Jude Children's Research Hospital
- Study site
- University of Colorado Hospital
- Registry record
- NCT06098430 · updated
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- Nuvalent Inc.
- Study site
- University of Colorado Cancer Center
- Registry record
- NCT05384626 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Aurora, CO on ClinicalTrials.gov.
Ask about studies near Aurora
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Colorado
All Colorado locations
314 studies recruiting across 31 cities.
Denver
131 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections